On Oct. 18, 2023, Novavax announced that Singapore’s Health Sciences Authority (HSA) has granted full approval for Novavax’s prototype COVID-19 vaccine Nuvaxovidﾙ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older. The Singapore Ministry of Health has included Nuvaxovid in the National Vaccination Programme as a protein-based non-mRNA option for COVID-19 prevention.